Compare Eos Energy Enterprises Inc (EOSE) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs GSK plc — how do they compare? Eos Energy Enterprises Inc trades at $2.6 (market cap $1.01B), while GSK plc trades at $46.47 (market cap $91.88B). The key difference: GSK plc is far larger — about 91× Eos Energy Enterprises Inc's market cap, and GSK plc pays a 3.9% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and GSK plc for 93 Days on average.
| EOSE | GSK | |
|---|---|---|
Market Cap | $1.01B | $91.88B |
Volume | 39,626,541 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $19.19 | $61.18 |
52-Week Low | $2.77 | $43.24 |
Typical Hold Time | 16 Days | 93 Days |
Enterprise Value | $1.34B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.645, down 14.68% in the last session, reflecting significant volatility amid mixed quarterly results. The company shows rapid revenue growth but deep losses, with a -246.76% net income margin in 2026. Recent developments include a $87 million DOE loan advance and a partnership with Google for a West Virginia energy project, highlighting growth potential in long-duration energy storage.
The outlook is bifurcated: strong revenue growth and strategic partnerships offer upside, but persistent losses and high debt-to-asset ratio of 91.87% pose substantial risks. Analyst consensus is cautious with a $7.10 price target, suggesting 168% potential upside, yet the bearish technical signal and negative cash flows from operations warrant careful monitoring of execution and funding needs.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
